These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 31489272)

  • 21. Normoglycemic diabetic ketoacidosis in a type 2 diabetes patient on dapagliflozin: A case report.
    Matli VVK; Fariduddin MM; Asafo-Agyei KO; Bansal N
    Clin Case Rep; 2021 Dec; 9(12):e05144. PubMed ID: 34917366
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [SGLT 2 inhibitors in Type 1 diabetes].
    Stougaard EB; Amadid H; Søndergaard E; Jørgensen ME; Persson F; Rossing P
    Ugeskr Laeger; 2020 Aug; 182(35):. PubMed ID: 32829747
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Euglycemic Diabetic Ketoacidosis with Elevated Acetone in a Patient Taking a Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor.
    Andrews TJ; Cox RD; Parker C; Kolb J
    J Emerg Med; 2017 Feb; 52(2):223-226. PubMed ID: 27717592
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Euglycemic Diabetic Ketoacidosis in a 27 year-old female patient with type-1-Diabetes treated with sodium-glucose cotransporter-2 (SGLT2) inhibitor Canagliflozin.
    Bader N; Mirza L
    Pak J Med Sci; 2016; 32(3):786-8. PubMed ID: 27375734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The DKA that wasn't: a case of euglycemic diabetic ketoacidosis due to empagliflozin.
    Candelario N; Wykretowicz J
    Oxf Med Case Reports; 2016 Jul; 2016(7):144-6. PubMed ID: 27471597
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prolonged Ketosis in a Patient With Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin.
    Pujara S; Ioachimescu A
    J Investig Med High Impact Case Rep; 2017; 5(2):2324709617710040. PubMed ID: 28589154
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SGLT-2 Inhibitors-a Culprit of Diabetic Ketoacidosis Postbariatric Surgery.
    Iqbal QZ; Mishiyev D; Niazi MR; Zia Z; Sattar SBA; Jahanghir A; Quyyumi S
    Case Rep Crit Care; 2020; 2020():8817829. PubMed ID: 33204542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Practical considerations for the use of sodium-glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes.
    Lam KS; Chow CC; Tan KC; Ma RC; Kong AP; Tong PC; Tsang MW; Chan TM; Tang SC; Lee KK; So WY; Tomlinson B
    Curr Med Res Opin; 2016 Jun; 32(6):1097-108. PubMed ID: 26933918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Euglycemic Diabetic Ketoacidosis Caused by SGLT2 Inhibitors and a Ketogenic Diet: A Case Series and Review of Literature.
    Mistry S; Eschler DC
    AACE Clin Case Rep; 2021; 7(1):17-19. PubMed ID: 33851013
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Commentary: SGLT inhibitors in type 1 diabetes: Place in therapy and a risk mitigation strategy for preventing diabetic ketoacidosis - the STOP DKA protocol.
    Rendell MS
    Diabetes Obes Metab; 2019 Oct; 21(10):2189-2191. PubMed ID: 31334593
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Case of SGLT2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis Following Coronary Artery Bypass Surgery.
    Osafehinti DA; Okoli OJ; Karam JG
    AACE Clin Case Rep; 2021; 7(1):20-22. PubMed ID: 33851014
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sodium-glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis; from Pathophysiology to Clinical Practice.
    Patoulias D; Manafis A; Mitas C; Avranas K; Lales G; Zografou I; Sambanis C; Karagiannis A
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):139-146. PubMed ID: 29412120
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sodium-Glucose Cotransporter-2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis in a Type 2 Diabetic Patient.
    Haddadin R; Aboujamra D; Iraninezhad H
    Cureus; 2023 Dec; 15(12):e51184. PubMed ID: 38283482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Euglycemic Diabetic Ketoacidosis Due to SGLT2 Inhibitor in a Patient With Gitelman Syndrome: A Therapeutic Dilemma.
    Ahmed T; Karimi H; Hegde V; Lodhi SH
    Cureus; 2021 Oct; 13(10):e19169. PubMed ID: 34873512
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute Pancreatitis-Induced Euglycemic Diabetic Ketoacidosis.
    Chaudhry A; Biggiani C; Afzal M; Chaudhry S; Vwich Y
    Cureus; 2021 Jun; 13(6):e15949. PubMed ID: 34336446
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Euglycemic diabetic ketoacidosis: A rare but serious side effect of sodium-glucose co-transporter 2 inhibitors.
    Lakušić N; Sopek Merkaš I; Slišković AM; Cerovec D
    World J Cardiol; 2022 Oct; 14(10):561-564. PubMed ID: 36339887
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Rare Case of Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis Obscured by Alkalosis.
    Fernandez Felix DA; Madrigal Loria G; Sharma S; Sharma S; Arias Morales CE
    Cureus; 2022 Jun; 14(6):e25818. PubMed ID: 35698468
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hyperglycemic, high anion-gap metabolic acidosis in patients receiving SGLT-2 inhibitors for diabetes management.
    Kum-Nji JS; Gosmanov AR; Steinberg H; Dagogo-Jack S
    J Diabetes Complications; 2017 Mar; 31(3):611-614. PubMed ID: 27913012
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Canagliflozin-Induced Diabetic Ketoacidosis: Case Report and Review of the Literature.
    Turner J; Begum T; Smalligan RD
    J Investig Med High Impact Case Rep; 2016; 4(3):2324709616663231. PubMed ID: 27635409
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials.
    Monami M; Nreu B; Zannoni S; Lualdi C; Mannucci E
    Diabetes Res Clin Pract; 2017 Aug; 130():53-60. PubMed ID: 28570924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.